MedTrace Logo

A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test

NCT00763204 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-02-27

No results posted yet for this study

Summary

The purpose of this study is to investigate dose-response relationship, antipsoriatic efficacy and safety of different concentrations of topical formulations with AN2728 in subjects with psoriasis vulgaris.

Conditions

Interventions

DRUG

AN2728 Cream, 2%

DRUG

AN2728 Cream, 1%

DRUG

AN2728 Cream, 0.3%

DRUG

AN2728 Cream Vehicle

DRUG

Betnesol®-V Creme, 0.1%

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-03-07
Completion
2008-03-07

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00763204 on ClinicalTrials.gov